Wegovy Price Per Month in 2026: The Actual Cash Math

The Wegovy price per month has four honest answers in 2026, and the one you pay depends on three things: whether you go through NovoCare's direct pharmacy, whether you have insurance that covers obesity drugs, whether you are on Medicare, and whether you are willing to use a compounded semaglutide program instead of the brand pen.

That is a real spread. On the retail end, a Wegovy 2.4 mg pen without insurance runs about $1,349 to $1,599 a month at CVS or Walgreens. On the manufacturer's own direct-to-patient pharmacy, the same pen is $349. New starters on the 0.25 mg and 0.5 mg pens get a promotional $199 for the first two months. The new Wegovy oral pill sits between $149 and $299 depending on dose. Medicare Part D members will get all doses for $50 a month starting July 1, 2026. And compounded semaglutide from licensed US telehealth clinics starts around $139 to $179 for the same 2.4 mg endpoint.

This guide breaks down each of those numbers, shows exactly what you get for the money in trial data, and tells you which price actually applies to your situation.

Bottom line: If you are a cash-paying US adult in 2026 and you want brand Wegovy, the working answer is $349 a month through NovoCare Pharmacy. If you are willing to use a compounded semaglutide program on the same molecule, you can be at $139 to $179 a month. The $1,349 retail number is real but rarely paid.

The four real Wegovy price tiers

There is no single Wegovy price per month, because Novo Nordisk operates a manufacturer direct pharmacy in parallel with retail wholesale. The four numbers below are the ones that actually get charged in 2026.

Where the Wegovy dosage chart shows the titration ladder from 0.25 mg to 2.4 mg over 16 to 20 weeks, this table shows what each week on that ladder costs. The dose escalates. The NovoCare price does not, which is what makes the ladder financially predictable for the first time since Wegovy launched.

What the $1,349 list price is really for

Novo Nordisk publishes a Wegovy list price of $1,349.02 per monthly pack. That number is the wholesale-acquisition benchmark that flows into pharmacy benefit manager rebate math and insurance actuarial models. It is not what a cash payer sees at retail, and it is not what most insured patients pay after their plan applies its discount.

Retail cash without NovoCare has come down from that list price to a $1,349 to $1,599 range in 2026. Costco Pharmacy is the low anchor, at roughly $1,299 to $1,399 depending on region. CVS and Walgreens sit at $1,399 to $1,549. Grocery-store pharmacies fall between. The prices are all charged against the same 2.4 mg pen (four 0.68 mL prefilled injectors), so this variance is pure retail markup, not a difference in what you receive.

The reason to name this tier at all is that the number gets quoted constantly in articles that pretend the direct pharmacy does not exist. It does. NovoCare Pharmacy has been shipping Wegovy nationally since March 2025. Anyone paying $1,349 in September 2026 is doing so because they did not know NovoCare is an option or because their prescriber did not send the script there.

NovoCare Pharmacy: the real cash floor at $349

NovoCare launched at $499 a month across all doses. Novo cut that to $349 in a step change that also introduced a $199 intro on the two starter doses. That is the price a self-pay adult should compare every other option against.

Concrete rules for 2026:

• $349 a month covers 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and the maintenance 2.4 mg dose. Each ship contains a monthly pack of four weekly single-use pens.
• $399 a month covers the newer Wegovy HD 7.2 mg dose. The extra $50 reflects both the higher milligram content and the fact that HD-eligible patients are typically maintenance patients rather than starters. For what HD buys in extra weight loss, the Wegovy HD 7.2 mg STEP UP trial guide walks through the 20.7% mean weight reduction at 72 weeks that anchored the new dose.
• $199 introductory covers the 0.25 mg and 0.5 mg starter doses for the first two monthly fills only. It steps to $349 on the third fill regardless of which dose you titrate to.
• No insurance required. NovoCare is a direct-to-patient cash channel. You do need a valid prescription from a US-licensed clinician, and you need to be a US adult with the FDA-approved indication (BMI 30, or 27 with a weight-related comorbidity, or the new cardiovascular indication).

The reason the $349 number matters is that it is roughly a quarter of what pharmacies were charging cash pay in 2024, and it makes injectable brand Wegovy roughly competitive with the price the compounded telehealth market set as its high anchor. A year ago the compounded advantage was $200 a month. Today it is closer to $150.

The Wegovy pill and OASIS 4

The oral Wegovy tablet is the same molecule as the injection, delivered orally at higher doses because the SNAC-enhanced absorption of oral semaglutide is still low-teens percent bioavailability. It is FDA-approved for chronic weight management as of December 2025. NovoCare cash prices are:

• $149 a month for the 1.5 mg pill.
• $199 a month for the 4 mg pill.
• $299 a month for the 9 mg and 25 mg pills.

The 25 mg dose is the efficacy dose in the OASIS 4 trial. In 307 adults with obesity but without diabetes, once-daily oral semaglutide 25 mg produced a mean weight reduction of 13.6% at 64 weeks, versus 2.4% on placebo, with 63% of participants losing at least 10% of their body weight (Aronne et al., NEJM 2025, PMID 40934115). That result is not identical to the injection: the STEP 1 injectable produced roughly 14.9% at 68 weeks in a much larger cohort (Wilding et al., NEJM 2021, PMID 33567185), and STEP 5 sustained a mean 15.2% reduction at 104 weeks (Garvey et al., Nat Med 2022, PMID 36216945). The pill and pen converge at roughly the same end-of-year weight reduction inside a percentage point.

For a monthly cost comparison, the pill is the cheapest way to enter the Wegovy brand ecosystem, especially at the 1.5 mg starter step. It also removes the injection-hesitation barrier, which is not trivial. The tradeoff is a stricter dosing window: oral semaglutide must be taken on an empty stomach with a small volume of plain water, at least 30 minutes before food, other medications, or other liquids. Miss that window and absorption drops toward zero. The injection has no such requirement.

Tip: If you are torn between the injection at $349 and the pill at $149, the deciding question is whether you can hold a 30-minute empty-stomach window at the same time every day. If not, the injection buys back that adherence for $200. If yes, the pill is genuinely $150 cheaper at maintenance.

Insurance coverage: SELECT changed the argument, coverage did not follow completely

The single biggest change in Wegovy's economics is that the FDA added a cardiovascular risk-reduction indication to the label alongside the weight-loss indication. In the SELECT trial, semaglutide 2.4 mg in 17,604 adults with prior cardiovascular disease and obesity but no diabetes cut major adverse cardiovascular events (MACE) by 20%, from 8.0% to 6.5% over a mean 34 months (Lincoff et al., NEJM 2023, PMID 37952131). The FDA relied on that finding when it added the cardiovascular indication.

For insurance coverage, that is the key. Plans that exclude "weight loss drugs" are legally allowed to do so. Plans that cover cardiovascular disease prevention have a harder time excluding a drug with an FDA cardiovascular indication. In practice, roughly three-quarters of large employer plans covered Wegovy in some form as of 2026, but the covered plans typically require prior authorization, a documented cardiovascular indication or high-BMI qualifier, and step therapy through cheaper drugs. A patient inside those requirements can hit $0 to $200 a month with the Wegovy savings card. A patient outside them pays cash and is back at the NovoCare $349 tier.

If you are on Medicare, the more direct path is the Medicare GLP-1 Bridge, which starts July 1, 2026. Novo Nordisk and CMS have agreed to a $50 per month flat price for every Wegovy dose (injection and pill) for Medicare Part D members whose plans participate. It is not universal across all Part D plans in the first cycle, but the participating plans list is expanding through 2026 and 2027. It is the cheapest legitimate path for anyone over 65 who can qualify for the indication.

Compounded semaglutide: the real Wegovy alternative

Wegovy's cash competition is not Zepbound or Rybelsus. It is compounded semaglutide from LegitScript-verified telehealth clinics. Compounded semaglutide is not a copy of Wegovy in the trademark sense. It is the same active molecule, prepared under a 503A or 503B pharmacy license and shipped at 2.5 to 10 mg per mL concentrations that allow a maintenance patient to titrate to the same 2.4 mg weekly equivalent the injectable pen delivers.

Real-world 2026 telehealth pricing for compounded semaglutide:

The delta between $139 and $349 is the money question for anyone paying cash. Compounded semaglutide costs about 40% of NovoCare Wegovy on the maintenance dose. Over a year, that is roughly $2,500 in savings on the same molecule. The cheapest semaglutide without insurance in 2026 guide has the current lineup ranked by verified per-mg cost.

The tradeoff is not efficacy at the molecule level. It is regulatory and supply predictability. FDA-approved Wegovy is manufactured to one specification and one supply chain. Compounded semaglutide is regulated at the pharmacy level, with variability in reconstitution ratios, preservative choice, and batch testing between providers. A LegitScript-verified pharmacy with per-batch COAs, US-licensed clinicians, and consistent titration protocols closes most of that gap. A random gray-market vial does not. For the underlying dose math on non-standard concentrations, the reconstitution calculator handles the unit conversions.

Warning: The FDA's 2024 semaglutide shortage designation ended in early 2025, which technically restricts 503B outsourcing facilities from mass-compounding semaglutide. Individualized 503A patient-specific compounding remains legal. The practical effect is that reputable compounders now dispense to named prescriptions rather than pre-filled inventory. That is a sourcing detail, not a red flag.

Which price you actually pay: the decision map

The three questions that determine your monthly Wegovy cost, in order:

1. Do you have commercial insurance that covers obesity drugs and a documented qualifier? If yes, the Wegovy savings card path is the cheapest, at $0 to $200 a month. Ask your prescriber to run the prior authorization before you commit to any cash path.
2. Are you on Medicare Part D with a plan that participates in the GLP-1 Bridge? If yes, $50 a month starting July 1, 2026, is the cheapest legitimate path.
3. Are you comfortable using a compounded semaglutide telehealth program instead of brand Wegovy? If yes, $139 to $179 a month for compounded semaglutide is the cash-pay floor. If no, NovoCare's $349 is the brand-Wegovy cash floor.

Only if none of those apply do you end up at retail cash without NovoCare, and the answer there is to switch prescriptions to NovoCare rather than pay $1,349.

For a broader cash-pay comparison across the whole GLP-1 class, including tirzepatide, the cheapest GLP-1 access hub keeps the current per-month numbers by molecule and provider, and the how much is tirzepatide without insurance guide covers the parallel per-mg math on the Zepbound side. If you are also weighing Wegovy against Zepbound on efficacy rather than price, Wegovy vs Zepbound walks through SURMOUNT-5, where tirzepatide beat semaglutide 20.2% vs 13.7% mean weight reduction at 72 weeks (Aronne et al., NEJM 2025, PMID 40353578). The Ozempic vs Wegovy piece covers the same-molecule-two-brand pricing question the marketing rarely names.

What you are actually buying at any price tier

The prices above pay for one of the best-studied weight-loss molecules in the modern literature. Semaglutide 2.4 mg produced a mean 14.9% weight reduction at 68 weeks in the pivotal STEP 1 trial in 1,961 adults, versus 2.4% on placebo (Wilding et al., NEJM 2021, PMID 33567185). STEP 5 extended that to 104 weeks in 304 participants and showed the loss largely holds: a mean 15.2% reduction sustained at two years (Garvey et al., Nat Med 2022, PMID 36216945).

The one number worth budgeting for that the SERP rarely shows: what happens if you stop. STEP 4 randomized 803 participants who had reached 2.4 mg maintenance to either continued weekly semaglutide or placebo for 48 weeks. Continued semaglutide extended weight loss to about 17.4% total, versus a 6.9% rebound in the placebo-switched arm (Rubino et al., JAMA 2021, PMID 33755728). Regain is not sudden. It is roughly two-thirds of lost weight over the year after discontinuation, on population averages. For monthly-cost planning, that means Wegovy is not a fixed 12-month course. It is an indefinite maintenance therapy, and the multi-year cash math is the honest way to think about the sticker.

The full semaglutide dosing reference shows the milligram-level titration and reconstitution math if you are working with research-grade material rather than the pen. For the oral 25 mg question specifically, the oral semaglutide (Rybelsus vs Orforglipron) guide walks the pill-format field end to end.

Final cost-per-percent-lost math

One useful reframe: on the NovoCare $349 injection, at a mean 15.2% weight loss at 104 weeks (STEP 5), you are paying about $460 per percentage-point of body weight lost, held for two years. On the Wegovy pill at $149 for the starter 1.5 mg step and $299 at the 25 mg efficacy dose, the endpoint math looks similar because OASIS 4 landed at 13.6% mean loss at 64 weeks. On compounded semaglutide at $139 a month, the same 15% endpoint costs closer to $180 per percentage-point, assuming the compounded product hits Wegovy-comparable adherence and titration.

Those are not identical products from a regulatory standpoint. They are approximately identical products from a mean-outcome standpoint, and the price gap is the tax on brand identity, packaging, and supply-chain single-sourcing. Whether that tax is worth paying is a personal decision. Wegovy at $349 is finally an honest number for what a top-tier weight-loss drug should cost. Compounded semaglutide at $139 is what the same molecule costs when the middleman is a compounding pharmacy rather than Novo Nordisk.

Bottom line: In 2026, the working Wegovy price per month is $349 direct from Novo Nordisk, $50 for Medicare Part D members on the Bridge, or $139 to $179 for compounded semaglutide on the same molecule. The $1,349 retail number is a benchmark, not a bill.

Disclaimer

This article is for educational and research purposes only and is not medical advice. Wegovy is a prescription medication approved for chronic weight management and cardiovascular risk reduction in eligible adults. Pricing information reflects publicly disclosed 2026 rates and manufacturer programs; actual out-of-pocket cost depends on your prescriber, pharmacy, plan, and eligibility. Any decision to start, stop, switch, or compound a GLP-1 medication should be made with a licensed clinician who knows your full medical history and current medications.